摘要
慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)是一种慢性B淋巴细胞增殖性疾病。随着人们对CLL/SLL在临床和分子水平上的深入了解,CLL/SLL的新型治疗方案也不断涌现,包括靶向治疗、嵌合抗原受体T细胞免疫疗法和异基因造血干细胞移植。其中靶向治疗包括:布鲁顿氏酪氨酸激酶抑制剂、磷脂酰肌醇3激酶抑制剂、B细胞淋巴瘤因子2抑制剂和蛋白激酶Cβ抑制剂。除新型药物的不断涌现,各疗法之间的联合治疗和对固定疗程的探索在CLL/SLL的治疗中也备受关注。文章结合相关文献对CLL/SLL的最新治疗进展进行总结。
Chronic lymphoblastic leukemia(CLL)/small lymphocytic lymphoma(SLL)is a chronic B lymphocyte proliferative disease.With the in-depth understanding of the clinical and molecular level of CLL/SLL,new treatments for CLL/SLL continue to emerge,including targeted therapy,chimeric antigen receptor T-cell immunotherapy and allogeneic hematopoietic stem cell transplantation.Targeted therapy includes Bruton's tyrosine kinase inhibitors,phosphoinositide 3 kinase inhibitors,B cell lymphoma 2 inhibitors,and protein kinase Cβinhibitors.In addition to the continued emergence of novel drugs,combination therapy and the exploration of treatment duration are of increasing interest in CLL/SLL.This article will comprehensively describe the latest treatment progress of CLL/SLL combined with the relevant literature.
作者
谭巧云
文秋月
张利玲
Tan Qiaoyun;Wen Qiuyue;Zhang Liling(Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology/Hubei Key Laboratory of Precision Radiation Oncology/lnstitute of Radiation Oncology Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)
出处
《中国肿瘤临床与康复》
2023年第4期230-237,共8页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
慢性淋巴细胞白血病/小淋巴细胞淋巴瘤
治疗
临床疗效
Chronic lymphoblastic leukemia/small lymphocytic lymphoma
Therapy
Clinical treatment efficacy
